227 related articles for article (PubMed ID: 32504034)
21. Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.
Tray N; Taff J; Singh B; Suh J; Ngo N; Kwa M; Troxel AB; Chae YK; Kurzrock R; Patel SP; Sharon E; Denkert C; Ross JS; Adams S
Breast; 2019 Apr; 44():29-32. PubMed ID: 30609392
[TBL] [Abstract][Full Text] [Related]
22. Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers.
Arciero CA; Diehl AH; Liu Y; Sun Q; Gillespie T; Li X; Subhedar P
J Surg Oncol; 2020 Nov; 122(6):1232-1239. PubMed ID: 32668059
[TBL] [Abstract][Full Text] [Related]
23. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.
Vranic S; Marchiò C; Castellano I; Botta C; Scalzo MS; Bender RP; Payan-Gomez C; di Cantogno LV; Gugliotta P; Tondat F; di Celle PF; Mariani S; Gatalica Z; Sapino A
Hum Pathol; 2015 Sep; 46(9):1350-9. PubMed ID: 26208846
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Ali SM; Wang K; Khaira D; Palma NA; Chmielecki J; Palmer GA; Morosini D; Elvin JA; Fernandez SV; Miller VA; Stephens PJ; Cristofanilli M
Breast Cancer Res Treat; 2015 Nov; 154(1):155-62. PubMed ID: 26458824
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.
Huang RSP; Haberberger J; McGregor K; Mata DA; Decker B; Hiemenz MC; Lechpammer M; Danziger N; Schiavone K; Creeden J; Graf RP; Strowd R; Lesser GJ; Razis ED; Bartsch R; Giannoudis A; Bhogal T; Lin NU; Pusztai L; Ross JS; Palmieri C; Ramkissoon SH
Oncologist; 2021 Oct; 26(10):835-844. PubMed ID: 34105210
[TBL] [Abstract][Full Text] [Related]
27. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
[TBL] [Abstract][Full Text] [Related]
28. A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas.
Dias-Santagata D; Lam Q; Bergethon K; Baker GM; Iafrate AJ; Rakheja D; Hoang MP
Mod Pathol; 2011 Jul; 24(7):974-82. PubMed ID: 21423156
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
[TBL] [Abstract][Full Text] [Related]
30. Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations.
Freitag CE; Mei P; Wei L; Parwani AV; Li Z
Hum Pathol; 2020 Aug; 102():94-103. PubMed ID: 32445652
[TBL] [Abstract][Full Text] [Related]
31. Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer.
Saridakis A; Berger ER; Harigopal M; Park T; Horowitz N; Le Blanc J; Zanieski G; Chagpar A; Greenup R; Golshan M; Lannin DR
Ann Surg Oncol; 2021 Oct; 28(10):5610-5616. PubMed ID: 34426884
[TBL] [Abstract][Full Text] [Related]
32. The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas.
Skálová A; Stenman G; Simpson RHW; Hellquist H; Slouka D; Svoboda T; Bishop JA; Hunt JL; Nibu KI; Rinaldo A; Vander Poorten V; Devaney KO; Steiner P; Ferlito A
Am J Surg Pathol; 2018 Feb; 42(2):e11-e27. PubMed ID: 29076877
[TBL] [Abstract][Full Text] [Related]
33. Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Montagna E; Cancello G; Pagan E; Bagnardi V; Munzone E; Dellapasqua S; Viale G; Mazzarol G; Veronesi P; Galimberti V; Santomauro G; Colleoni M
Breast; 2020 Oct; 53():138-142. PubMed ID: 32795829
[TBL] [Abstract][Full Text] [Related]
34. Tumor Mutational Burden and
Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.
Dalin MG; Desrichard A; Katabi N; Makarov V; Walsh LA; Lee KW; Wang Q; Armenia J; West L; Dogan S; Wang L; Ramaswami D; Ho AL; Ganly I; Solit DB; Berger MF; Schultz ND; Reis-Filho JS; Chan TA; Morris LG
Clin Cancer Res; 2016 Sep; 22(18):4623-33. PubMed ID: 27103403
[TBL] [Abstract][Full Text] [Related]
36. Colorectal Adenocarcinomas Harboring ALK Fusion Genes: A Clinicopathologic and Molecular Genetic Study of 12 Cases and Review of the Literature.
Lasota J; Chłopek M; Wasąg B; Kowalik A; Christiansen J; Lamoureux J; Kuźniacka A; Felisiak-Gołąbek A; Liu Y; Reyes TAR; Saha R; Agaimy A; Behenska K; Biernat W; Cattaneo L; Centonze G; Daum O; Daumova M; Domagała P; Dziuba I; Geppert CE; Góźdź S; Nasierowska-Guttmejer A; Hałoń A; Hartmann A; Inaguma S; Iżycka-Świeszewska E; Kaczorowski M; Kołos M; Kopczyński J; Michal M; Milione M; Okoń K; Pęksa R; Pyzlak M; Ryś J; Waloszczyk P; Wejman J; Miettinen M
Am J Surg Pathol; 2020 Sep; 44(9):1224-1234. PubMed ID: 32804454
[TBL] [Abstract][Full Text] [Related]
37. The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
Barrett MT; Lenkiewicz E; Malasi S; Basu A; Yearley JH; Annamalai L; McCullough AE; Kosiorek HE; Narang P; Wilson Sayres MA; Chen M; Anderson KS; Pockaj BA
Breast Cancer Res; 2018 Jul; 20(1):71. PubMed ID: 29996881
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.
Joneja U; Vranic S; Swensen J; Feldman R; Chen W; Kimbrough J; Xiao N; Reddy S; Palazzo J; Gatalica Z
J Clin Pathol; 2017 Mar; 70(3):255-259. PubMed ID: 27531819
[TBL] [Abstract][Full Text] [Related]
39. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
[TBL] [Abstract][Full Text] [Related]
40. Uncovering the genomic heterogeneity of multifocal breast cancer.
Desmedt C; Fumagalli D; Pietri E; Zoppoli G; Brown D; Nik-Zainal S; Gundem G; Rothé F; Majjaj S; Garuti A; Carminati E; Loi S; Van Brussel T; Boeckx B; Maetens M; Mudie L; Vincent D; Kheddoumi N; Serra L; Massa I; Ballestrero A; Amadori D; Salgado R; de Wind A; Lambrechts D; Piccart M; Larsimont D; Campbell PJ; Sotiriou C
J Pathol; 2015 Aug; 236(4):457-66. PubMed ID: 25850943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]